Background:
The Tablo® Hemodialysis System is an all in one, easy-to-learn device capable of achieving clearance goals in as little as three treatments per week. It features integrated water purification, on-demand dialysate production and two-way wireless data transmission.

Tablo obtained FDA clearance for Home Hemodialysis (HHD) in March 2020 based on a prospective, cross-over between in-center and at home dialysis trial (NCT02460263).

Tablo met all safety and effectiveness endpoints, reported high rates of treatment adherence and patient retention, with greatly reduced training time.

Results:
- Average training time was 7.4 training days.
- Patient retention was 100% with no patients opting out of HHD with Tablo.
- Mean prescribed treatment time was 3.2 hours with a mean frequency of 3.7 treatments per week.
- Mean UF rate per treatment was 7.3 mL/kg/hr.
- Treatment adherence was 93%, with 95% of treatments completing within 10% of prescribed time.
- The mean number of clinically significant alarms per treatment was 1.0 (± 3.0), with an average time to resolution of 10.7 (± 18.5) seconds.

This data supports that Tablo is capable of successfully achieving clinical goals while reducing the overall patient burden often associated with HHD.

Conclusion:
Results from the Tablo IDE trial are reproducible in the real world at a frequency of 3-4 treatments/week.

Treatment Results

<table>
<thead>
<tr>
<th>Variable</th>
<th>Treatment Data (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Weight (kg)</td>
<td>89.8 ± 25.4</td>
</tr>
<tr>
<td>Actual Treatment Time (hrs)</td>
<td>3.2 ± 0.8</td>
</tr>
<tr>
<td>Actual UF Rate (mL/kg/hr)</td>
<td>7.3 ± 4.1</td>
</tr>
</tbody>
</table>

Tablo is easy to use, with minimal burden on patients:
- ✔ 100%Retention Rate
- ✔ 95.4% Treatment Success
- ✔ 93.2% Treatment Adherence
- ✔ 27.4 hours over 7.9 sessions of Tablo Training
- ✔ 1.0 Alarm per Treatment
- ✔ 10.7 seconds to Alarm Resolution

Observed averages for first 20 patients and 1,000 treatments.